Compare APT & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | APT | KPTI |
|---|---|---|
| Founded | 1983 | 2008 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 53.3M | 47.6M |
| IPO Year | 1997 | 2013 |
| Metric | APT | KPTI |
|---|---|---|
| Price | $5.36 | $1.79 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $16.00 |
| AVG Volume (30 Days) | 35.9K | ★ 1.2M |
| Earning Date | 05-08-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.24 | N/A |
| Revenue | $59,142,000.00 | ★ $146,067,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $22.36 |
| P/E Ratio | $22.13 | ★ N/A |
| Revenue Growth | ★ 2.25 | 0.57 |
| 52 Week Low | $4.34 | $1.72 |
| 52 Week High | $7.50 | $10.99 |
| Indicator | APT | KPTI |
|---|---|---|
| Relative Strength Index (RSI) | 51.23 | 26.02 |
| Support Level | $5.13 | N/A |
| Resistance Level | $5.35 | $2.18 |
| Average True Range (ATR) | 0.18 | 0.16 |
| MACD | -0.01 | 0.23 |
| Stochastic Oscillator | 27.91 | 5.95 |
Alpha Pro Tech Ltd is in the business of protecting people, products, and environments. It is developing, manufacturing, and marketing a line of disposable protective apparel and infection control products for the cleanroom, industrial, pharmaceutical, medical, and dental markets. It also manufactures a line of building supply construction weatherization products that are sold under the Alpha Pro Tech brand name. The Company operates through two business segments: Building Supply and Disposable Protective Apparel. Key revenue is generated from Building Supply, consisting of a line of construction supply weatherization products. The construction supply weatherization products consist of housewrap and synthetic roof underlayment, and synthetic roof underlayment accessories.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company focused on novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company conducts research focused on intracellular communication between the nucleus and cytoplasm and has developed small-molecule compounds that inhibit exportin 1 (XPO1), a nuclear export protein. It is focused on marketing XPOVIO (selinexor).